These findings highlight the opposing roles of BAF60a and BAF60c in vascular diseases such as AAA and atherosclerosis, suggesting that their targeted modulation could offer novel therapeutic strategies with significant clinical potential. This evidence concerns the gene SMARCD3 and triple-A syndrome.